Japan
MabGenesis Inc., founded in 2019, is a biopharmaceutical startup based in Yokohama, Japan. The company specializes in the discovery of innovative therapeutic antibodies aimed at enhancing both human and animal health. Utilizing over 30 years of academic research, MabGenesis boasts a powerful technology platform that includes high-quality phage display antibody libraries, known as MOURA Libraries, and efficient antibody isolation technology called IMPACT. These technologies enable the rapid and efficient isolation of 100% species-specific monoclonal antibodies.
The company positions itself prominently within the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. Their last reported funding was a ¥240.00M Series A round on June 1, 2020, with participation from investors such as SMBC Venture Capital, Beyond Next Ventures, （株）宮崎銀行, and ANNIVERSAIRE. As a private entity, MabGenesis continues to leverage its innovative capabilities to address the complex challenges of therapeutic antibody discovery.
